Pathological Effects of SARS-CoV-2 Associated with Hematological Abnormalities.

Area of Science:

• Hematology
• Infectious Diseases
• Critical Care Medicine

Background:

• The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused significant global health issues.
• COVID-19 infection impacts multiple organ systems, notably the hematologic system, leading to severe complications.
• Hematologic abnormalities, including thrombocytopenia and lymphopenia, are linked to adverse outcomes in COVID-19 patients.

Purpose of the Study:

• To highlight the hematologic complications associated with COVID-19.
• To emphasize the importance of early recognition and management of thrombotic events in COVID-19 patients.
• To discuss the role of anticoagulation in mitigating COVID-19-related morbidity and mortality.

Main Methods:

• Review of current literature on COVID-19 pathophysiology and hematologic manifestations.
• Analysis of clinical data regarding thrombotic events and coagulation abnormalities in COVID-19.
• Examination of biomarker profiles (LDH, D-dimer, ferritin, CRP) in severe COVID-19 cases.

Main Results:

• COVID-19 can trigger a cytokine storm and intravascular thrombosis, leading to arterial and venous thromboses.
• Common hematologic findings include thrombocytopenia, lymphopenia, and neutrophilia, correlating with poor prognosis.
• Elevated biomarkers like LDH, D-dimer, ferritin, and CRP are indicative of severe COVID-19 and unfavorable outcomes.

Conclusions:

• Prompt recognition and therapeutic anticoagulation are crucial for managing COVID-19-associated coagulation disorders.
• Understanding the pathophysiology, including cytokine storm and thrombosis, is key to effective COVID-19 patient management.
• Prophylactic anticoagulation plays a vital role in preventing severe complications and reducing mortality rates in COVID-19.